Meprolen (Omeprazole Sodium)

Meprolen, a proton pump inhibitor, is used in conditions where suppression of gastric acid is required.

• Gastric ulcer: promotes healing by reducing gastric acid secretion.
• Duodenal ulcer: accelerates ulcer resolution through acid suppression.
• Gastro‑oesophageal reflux disease (GERD): alleviates reflux symptoms by lowering stomach acidity.
• Stress‑related mucosal damage: provides prophylaxis against stress ulcers in critically ill patients.

• Omeprazole irreversibly binds to the H+/K+ ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By inhibiting this pump, it blocks the final step of gastric acid production, leading to a sustained reduction in gastric acidity and allowing mucosal healing.

Adverse reactions may occur with any medication. Patients should be monitored for both common and serious events.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: watery stools, usually transient.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild discomfort in the stomach area.
• Flatulence: increased intestinal gas.
• Injection site reactions: erythema or mild pain.

Serious or Rare Side Effects

• Severe allergic reaction: rash, itching, swelling, or anaphylaxis.
• Clostridioides difficile infection: persistent diarrhoea with abdominal cramping.
• Hypomagnesemia: low serum magnesium levels, potentially causing muscle cramps or arrhythmias.
• Hepatic dysfunction: elevated liver enzymes or jaundice.
• Bone fracture risk: long‑term use may be associated with decreased bone density.
• Acute interstitial nephritis: kidney inflammation presenting with reduced urine output.

Before initiating therapy, clinicians should consider patient‑specific factors and monitor for potential complications.

• Renal impairment: adjust therapy and monitor renal function.
• Hepatic impairment: use with caution; monitor liver enzymes.
• Known hypersensitivity: avoid if patient has previous allergic reaction to omeprazole or other PPIs.
• Elderly patients: start at the lowest effective dose and monitor for adverse effects.
• Concomitant medications: review for possible drug interactions.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs. Interaction severity varies.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk.
• Atazanavir: decreased antiviral efficacy due to reduced gastric acidity.
• Methotrexate: increased serum levels, raising toxicity risk.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, requiring closer coagulation monitoring.
• Digoxin: possible rise in serum digoxin concentrations.
• Phenytoin: reduced phenytoin levels, may necessitate dose adjustment.
• Ketoconazole: decreased antifungal absorption, consider alternative therapy.
• Rifampin: may lower omeprazole concentrations, monitor therapeutic response.